Cidara治疗 CDTX 深 沪
等待开盘 09-25 09:30:00 美东时间
87.805
+14.315
+19.48%
华盛通- 最 高88.64
- 今 开77.40
- 成交量 189.31万股
- 最 低 77.00
- 昨 收 73.49
- 总市值 11.39亿
- 52周最高 88.64
- 市盈率 静 --
- 换手率 14.60%
- 52周最低 10.14
- 委 比 86.67%
- 总股本 1296.98万
- 历史最高 382.60
- 量 比 4.22
- 振 幅 15.84%
- 历史最低 8.00
- 每 手 1
- 风险率 2.15%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Cidara Therapeutics Announces Expanded and Accelerated Phase 3 Plan for CD388, a Non-Vaccine Preventative of Seasonal Influenza
Cidara Therapeutics更新了CD388的第三阶段临床试验计划，根据FDA的反馈加速了时间表，提前在2025年秋季启动。试验将扩展至65岁以上的成年人，并包括有高度风险共病和免疫力低下的受试者，预期能覆盖超过10000万潜在参与者，以更好地满足流感预防的需求。
09-24 11:00
美股大行评级 | 潜在涨幅1650.0%！Ascendiant Capital维持GRI Bio"买入"评级，目标价上调至35美元
今日重点评级关注：Ascendiant Capital：维持GRI Bio"买入"评级，目标价从34美元升至35美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从7.5美元升至7.75美元
09-23 09:52
Cidara Therapeutics Presents Data On CD388 From Phase 2b NAVIGATE Trial And Preclinical Studies Against H5N1
- Efficacy and safety results from successful NAVIGATE Phase 2b trial of CD388 for prevention of influenza illness featured in late-breaking presentation- Preclinical data demonstrating potential efficacy of CD388 to
09-17 20:05
Candel Therapeutics to Present Phase 3 Results of CAN-2409 in Localized Prostate Cancer at ASTRO 2025
Candel Therapeutics will present CAN-2409 Phase 3 trial data for intermediate-to-high-risk localized prostate cancer at ASTRO 2025. The oral presentation, featuring Glen Gejerman, MD, MBA, highlights CAN-2409's combination with external beam radiation. The abstract was selected for ASTRO’s Science Highlights. CAN-2409 has received multiple FDA designations, including Fast Track and Orphan Drug, and demonstrated positive results in phase 2a trials...
09-17 12:05
Cidara Therapeutics to Participate in September Investor Conferences
Cidara Therapeutics announced it will participate in two September investor conferences: the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025, with a corporate presentation at 4:00 PM ET, and the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9, 2025, featuring a fireside chat at 7:00 AM ET. The company will also engage in one-on-one investor meetings during these events. Cidara uses its Cloudbre...
09-04 12:00
Cidara Therapeutics To Present Two Oral Sessions, Including Late-Breaking, At ISRV AVG And IMRP Meetings
Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced it will have two oral presentations,
09-03 20:06
Cidara Therapeutics to Present Clinical Phase 2b Data and Preclinical H5N1 Data on CD388 at ISRV’s 8th AVG and 3rd IMRP 2025 Meeting
Cidara Therapeutics will present two oral abstracts at the ISRV/IMRP conference in Singapore, September 17-20, 2025. The late-breaking presentation, "NAVIGATE: Phase 2b Trial of CD388 for Influenza Prevention," by Dr. Rick Bright will discuss trial results on healthy adults. Additionally, Dr. Andreev Konstantin will present "Single Dose of CD388 Protects Against H5N1 in Ferret Model" in a parallel session. CD388, Cidara's lead DFC candidate, aims...
09-03 12:00
Guggenheim Keeps Their Buy Rating on Cidara Therapeutics (CDTX)
Guggenheim analyst Seamus Fernandez reiterated a Buy rating on Cidara Therapeut...
09-02 19:15
Regeneron Announces Positive Results from Phase 3 Trial in Generalized Myasthenia Gravis
Cemdisiran, an investigational siRNA targeting complement factor C5, met primary and key secondary endpoints in the Phase 3 NIMBLE trial for adults with generalized myasthenia gravis (gMG). Administered subcutaneously every three months, cemdisiran demonstrated a 2.3-point placebo-adjusted improvement in the Myasthenia Gravis Activities of Daily Living (MG-ADL) total score. The trial also evaluated cemdisiran combined with pozelimab (cemdi-poze),...
08-26 11:00
Cidara Therapeutics: Promising Trials Amidst Financial Challenges
Cidara Therapeutics Inc. (($CDTX)) has held its Q2 earnings call. Read on for t...
08-13 10:27
